CD19 and acute lymphoblastic leukemia: An earlier report, suggests that the CAPD is a sensitive screen for ICANS among patients with relapsed or refractory B‐ALL who were enrolled in phase I of an open label phase I/II clinical trial (clinicaltrials.gov NCT02028455) of CD19‐directed, 4‐1BB co-stimulated CAR T-cells (SCRI‐CAR19v1) (30).